Robert Burns
Recent Articles
Brisbane Biotech Showcases Degrader Pipeline Advantages at AACR 04/27/2026
Nurix Therapeutics (NASDAQ: NRIX) recently showcased AACR presentations that highlighted the mechanistic superiority of the company's protein degrader platform and preclinical data across key pipeline assets, NX-1607, NRX-4972.
MA Biotech Co. Downgraded to Sell After Second FDA CRL for RP-1 Melanoma BLA 04/13/2026
H.C. Wainwright downgraded Replimune Group (REPL:NASDAQ) to Sell after the FDA issued a second Complete Response Letter for the RP-1 plus Opdivo BLA in anti-PD1 failed melanoma.
Target Price Raised on Biotech Co. 09/25/2024
In an updated assessment of Zymeworks Inc.'s (ZYME:NYSE; ZYME:TSX) pipeline potential and upcoming catalysts, H.C. Wainwright & Co. analysts raised their target price on the company.
Due to permission requirements, not all quotes are shown.
